雷贝拉唑三联疗法治疗消化性溃疡66例疗效观察

126例消化性溃疡患者随机分成对照组60例应用雷贝拉唑10mg qd，疗程4周；治疗组66例应用雷贝拉唑10mg qd，疗程4周，阿莫西林0．75g tid、克托霉素0．5g bid，疗程1周。两组溃疡愈合率均达100％；治疗组H．pylori清除率95．5％，对照组25％；随诊所有患者2月、1年溃疡复发率，治疗组分别为6．7％、9．1％，对照组分别为33．3％、58．3％；无药物不良反应。结果表明雷贝拉唑三联疗法疗程短、高效、依从性好，无药物副作用，使用方便，溃疡复发率低。

Rabeprazole triple therapy for the treatment of peptic ulcer effect of 66 cases

One hundred and twenty-six cases of peptic ulcer patients were randomly divided into control group （60 cases） of Rabeprazole 10 mg qd for four weeks; the treatment group （66 cases） of Rabeprazole 10 mg qd for four weeks, Amoxicillin 0.75 g rid and Clarithromycin 0.5 g bid for one week. Two groups of patients with ulcer healing rate reached 100% , H. pylori treatment group 95.5% clearance rate and the control group 25% no adverse drug reactions. Follow-up with H. pylori infection and ulcer recurrence rate higher than the control group therapy group. So Rabeprazole triple therapy treatment short ulcer recurrence rate low.